- Home
- CELC vs QDEL Comparison
CELC vs QDEL Comparison
Compare CELC & QDEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELC
- QDEL
- Stock Information
- Founded
- CELC 2011
- QDEL 1979
- Country
- CELC United States
- QDEL United States
- Employees
- CELC N/A
- QDEL N/A
- Industry
- CELC Medical Specialities
- QDEL Medical Specialities
- Sector
- CELC Health Care
- QDEL Health Care
- Exchange
- CELC Nasdaq
- QDEL Nasdaq
- Market Cap
- CELC 2.3B
- QDEL 2.1B
- IPO Year
- CELC 2017
- QDEL N/A
- Fundamental
- Price
- CELC $51.88
- QDEL $28.12
- Analyst Decision
- CELC Strong Buy
- QDEL Hold
- Analyst Count
- CELC 5
- QDEL 6
- Target Price
- CELC $67.20
- QDEL $39.00
- AVG Volume (30 Days)
- CELC 1.1M
- QDEL 1.3M
- Earning Date
- CELC 11-13-2025
- QDEL 11-06-2025
- Dividend Yield
- CELC N/A
- QDEL N/A
- EPS Growth
- CELC N/A
- QDEL N/A
- EPS
- CELC N/A
- QDEL N/A
- Revenue
- CELC N/A
- QDEL $2,741,600,000.00
- Revenue This Year
- CELC N/A
- QDEL N/A
- Revenue Next Year
- CELC N/A
- QDEL $2.93
- P/E Ratio
- CELC N/A
- QDEL N/A
- Revenue Growth
- CELC N/A
- QDEL N/A
- 52 Week Low
- CELC $7.58
- QDEL $22.05
- 52 Week High
- CELC $63.06
- QDEL $49.45
- Technical
- Relative Strength Index (RSI)
- CELC 53.91
- QDEL 51.02
- Support Level
- CELC $45.15
- QDEL $25.48
- Resistance Level
- CELC $50.00
- QDEL $29.05
- Average True Range (ATR)
- CELC 3.48
- QDEL 1.45
- MACD
- CELC -0.04
- QDEL -0.16
- Stochastic Oscillator
- CELC 64.67
- QDEL 37.24
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
About QDEL QuidelOrtho Corporation
QuidelOrtho Corp is engaged in the development, manufacturing and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry and transfusion medicine which helps clinicians and patients to make decisions across the globe. Geographically the company has its presence in North America, EMEA, China and Other countries. It generates majority if its revenue from North America.